Prevention of Postpartum Hemorrhage With Tranexamic Acid
NCT05370820
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
In part 1 of the study, the investigators conducted a prospective, open-label, dose finding pharmacokinetic (PK) study in 43 pregnant 3rd trimester women scheduled for non-emergent cesarean section. The investigators administered three doses of the drug (5 mg/kg, 10 mg/kg and 15 mg/kg) in an escalating fashion by cohort with the lowest dose first. The drug was administered intravenously at the time of umbilical cord clamping for a non-emergent cesarean section. A maximum of 1 g was administered.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Post Partum Hemorrhage
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 50 years
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- Inova Health Care Services
- Last updated on ClinicalTrials.gov
- March 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
District of Columbia · 1
- George Washington University Hospital · Washington D.C., DC
Virginia · 1
- Inova Fairfax Medical Campus · Falls Church, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.